

Effects of dietary fiber intake on risk factors for cardiovascular disease in subjects at high risk

Ramon Estruch, Miguel Angel Martinez-Gonzalez, Dolores Corella, Josep Basora-Gallisá, Valentina Ruiz-Gutierrez, Maria Isabel Covas, Miguel Fiol, Enrique Gómez-Gracia, Mari Carmen Lopez-Sabater, Rosa Escoda, et al.

▶ To cite this version:

Ramon Estruch, Miguel Angel Martinez-Gonzalez, Dolores Corella, Josep Basora-Gallisá, Valentina Ruiz-Gutierrez, et al.. Effects of dietary fiber intake on risk factors for cardiovascular disease in subjects at high risk. Journal of Epidemiology and Community Health, 2009, 63 (7), pp.582-n/a. 10.1136/jech.2008.082214. hal-00477885

HAL Id: hal-00477885 https://hal.science/hal-00477885v1

Submitted on 30 Apr 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

EFFECTS OF DIETARY FIBER INTAKE ON RISK FACTORS FOR CARDIOVASCULAR DISEASE IN SUBJECTS AT HIGH RISK

Ramon Estruch, MD, PhD^{1,2,*}; Miguel Angel Martínez-González, MD, PhD³; Dolores Corella, MD, PhD^{2,4}; Josep Basora-Gallisá, MD⁵; Valentina Ruiz-Gutiérrez, PhD⁶; María Isabel Covas, PhD^{2,7}; Miguel Fiol, MD, PhD^{2,8}; Enrique Gómez-Gracia, MD, PhD⁹; Mari Carmen López-Sabater, PhD¹⁰; Rosa Escoda, MD¹; María Angeles Pena, DPharm¹¹; Javier Diez-Espino, MD³; Carlos Lahoz, MD, PhD¹²; José Lapetra, MD, PhD^{2,13}; Guillermo Sáez, MD, PhD¹⁴, and Emilio Ros, MD, PhD^{2,15} on behalf of the PREDIMED Study Investigators

¹Department of Internal Medicine, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona; ²Ciber Fisiopatologia de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III; ³Department of Preventive Medicine and Public Health, School of Medicine-Clinica Universitaria, University of Navarra; ⁴Department of Epidemiology, Preventive Medicine and Public Health, School of Medicine, University of Valencia; ⁵Direcció d'Atenció Primària Reus-Tarragona, Institut Català de la Salut, Human Nutrition Unit, School of Medicine, University Rovira i Virgili, Reus (Tarragona); ⁶Instituto de la Grasa, Conseio Superior de Investigaciones Científicas, Sevilla; ⁷Cardiovascular Epidemiology Unit, Municipal Institut for Medical Research (IMIM), Barcelona; ⁸Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Palma de Mallorca; ⁹Department of Epidemiology, School of Medicine, University of Malaga; ¹⁰Department of Nutrition and Bromatology, School of Pharmacy, Barcelona; ¹¹Clinical Trial Unit, Fundación LEIA-Hospital Txangorritxu, Vitoria; ¹²Arteriosclerosis Unit, Hospital Carlos III, Madrid; ¹³San Pablo Health Center, Sevilla; ¹⁴Department of Biochemistry, School of Medicine, University of Valencia; ¹⁵Lipid Clinic, Endocrinology and Nutrition Service, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain.

*Corresponding author: Dept. of Internal Medicine, Hospital Clinic, Villarroel, 170, 08036 Barcelona, Spain. Tel: +34-93-227-5465; fax: +34-93-227-5465. *E-mail address*: <u>restruch@clinic.ub.es</u>. *Number of words: 3014*

1 ABSTRACT

2 BACKGROUND:

3 Epidemiological studies and feeding trials with supplements suggest that fibre intake is

4 associated with a reduction in cardiovascular risk. However, the effects of changes in dietary

5 fibre on risk factor levels have not been evaluated in free-living individuals. Thus, we

6 assessed the 3-month effects of changes in dietary fibre intake on cardiovascular risk factors

7 in free-living high-risk subjects.

8 METHODS:

9 772 high-risk subjects (age 69±5 years) were assigned to a low-fat diet or 2 Mediterranean-

10 style diets. All participants received behavioural and nutritional education, including

11 recommendations for increasing the consumption of vegetables, fruits, and legumes. Changes

12 in food and nutrient intake, body weight, blood pressure, lipid profiles, glucose control, and

13 inflammatory markers were evaluated.

14 RESULTS:

15 Most participants increased consumption of vegetable products, but the increase in dietary

16 fibre exhibited wide between-subject variability (6-65 g/day). Body weight, waist

17 circumference, and mean systolic and diastolic blood pressure decreased across quintiles of

18 fibre intake (P <0.005; all). Reductions in fasting glucose and total cholesterol levels, and

19 increments in HDL cholesterol were highest among participants in the upper 20% of fibre

20 intake (P=0.04 and 0.02, respectively). Plasma concentrations of C-reactive protein, but not

21 those of inflammatory cytokines, decreased in parallel with increasing dietary fibre (*P*=0.04).

22 Significant reductions in LDL cholesterol were observed only among participants with the

23 greatest increases in soluble fibre intake (*P*=0.04).

24 CONCLUSIONS:

Increasing dietary fibre intake with natural foods is associated with reductions in classical and
 novel cardiovascular risk factors in a high risk cohort.

27

28 Number of words: 243

29

30 KEYWORDS: Dietary fibre; Atherosclerosis; Risk factors; Cardiovascular disease; Nutrition
 31

1 INTRODUCTION

2	The Mediterranean diet (Med-diet) has been has been widely considered as a model of healthy
3	eating. This dietary pattern is characterized by a high consumption of non-refined grains,
4	legumes, nuts, fruits and vegetables; relatively high intake of total fat, mainly derived from
5	olive oil; moderate to high intake of fish and poultry; dairy products (usually as yogurt or
6	cheese) in small amounts; low consumption of red meat and meat products; and moderate
7	alcohol intake, usually in the form of red wine with meals.[1] Thus, high consumption of
8	fibre-rich foods is one of the characteristic features of the Med-diet.
9	Dietary fibre (DF), a mixture of chemicals in indigestible vegetable residues,[2] has
10	received much attention in nutritional epidemiology. Observational studies have consistently
11	shown that DF intake is associated with reduced cardiovascular risk, including ischemic heart
12	disease [3-6] and stroke [5-8], and lower risk of diabetes [9-11]. Clinical trials have also
13	suggested that DF supplementation has beneficial effects on risk factors, such as blood
14	pressure, serum lipids, insulin sensitivity and diabetic metabolic control.[12-16] However, no
15	intervention study has evaluated the effects of DF on classical and novel risk factors in free-
16	living persons at high cardiovascular risk.
17	To address this issue, we evaluated the effects of 3-month changes in DF intake on
18	cardiovascular risk factors in a large sample of subjects at high risk for cardiovascular disease.
19	
20	MATERIAL AND METHODS
21	STUDY DESIGN
22	The PREDIMED study (PREvención con DIeta MEDiterránea) is a large multi-centre,
23	randomized 5-year clinical trial aimed at assessing the effects of the Med-diet on the primary
24	prevention of cardiovascular disease (CVD) in Spain (http://www.predimed.org). Up to
25	September 2008, this trial includes 6,988 high-risk participants allocated to 3 interventions:
26	Med-diet plus virgin oil, Med-diet plus nuts, and control diet (low-fat diet). The main

1 outcome for the whole trial is an aggregate of cardiovascular events (cardiovascular death, 2 non-fatal myocardial infarction, or non-fatal stroke). The Institutional Review Boards of the 3 participating centres approved the study protocol. This trial has been registered with the 4 International Standard Randomised Controlled Trial Number (ISRCTN) 35739639. The trial 5 design has been described in detail elsewhere.[17] 6 The present study was designed as a short-term trial in a subset of participants, namely 7 those entering the PREDIMED trial during the first 6 months of recruitment, to assess the

8 effects of changes in dietary fibre intake on surrogate markers of atherosclerosis.

9 PARTICIPANTS AND RECRUITMENT

10

Nine hundred thirty possible participants were evaluated. Eligible subjects were community-11

dwelling persons, aged 55-80 years for men and 60-80 years for women, who had either type

12 2 diabetes or 3 or more of the following CHD risk factors: current smoking, hypertension

13 (blood pressure>140/90 mmHg), LDL cholesterol \geq 160 mg/dL, low HDL cholesterol (\leq 40

mg/dL), body mass index (BMI≥25 kg/m²), or family history of premature CHD. Exclusion 14

15 criteria were: previous history of cardiovascular disease, any severe chronic illness, illegal

16 drug use or alcoholism, and low predicted likelihood of changing dietary habits.[18]

17 The primary care physicians based participants' eligibility on review of clinical records

18 and a screening visit. Suitable candidates were invited to attend a screening visit. This

19 included a face-to-face interview to inquire about medical conditions and risk factors related

20 to eligibility. More than 95 % of eligible candidates who met entry requirements signed an

21 informed consent and agreed to return for the baseline visit.

22 BASELINE ASSESSMENT AND INTERVENTION

23 We administered a validated 137-item food frequency questionnaire (FFQ),[19] and the

24 validated Spanish version[20] of the Minnesota Leisure Time Physical Activity questionnaire

25 in the baseline assessment. For each food included in the FFQ, a standard portion size (representing the serving size of that item most frequently consumed currently in Spain) was
 specified. DF intake was calculated by multiplying the frequency of consumption of each item
 by the fibre content of the specified serving, according to Spanish food composition
 tables.[21] The intra-class correlation coefficient comparing DF intake by FFQ with the
 average of four 3-day dietary records was 0.75. Anthropometric measurements, blood
 pressure, spot urine and fasting blood samples were obtained. All examinations were repeated
 at 3 months.

8 Trained dieticians were responsible for all aspects of the interventions and assisted 9 participants in completing the FFQ.^[22] Participants assigned to the control group received 10 personal advice together with a leaflet with written recommendations to follow a low-fat 11 diet.[23] Participants in the 2 Med-Diet intervention groups were given personalized advice 12 for dietary changes directed to achieve a diet closest to the traditional Med-diet. [22] 13 Depending on group assignment, participants were given free virgin olive oil or free sachets 14 of walnuts, hazelnuts, and almonds. In the 3 groups, the general guidelines included positive 15 recommendations for increase consumption of vegetables, fruits, legumes, fish and seafood, 16 and white meats instead of red meats. Negative recommendations included limiting and/or 17 eliminating presumed detrimental foods (red and processed meats, fat-rich dairy products, 18 commercial pastries, snacks, and sugar-sweetened beverages). Thus, all intervention diets 19 coincided in the recommendation to increase fibre-rich foods, a reason why the 3 intervention 20 groups are grouped as a single one for the comparisons of fibre intake and change in risk 21 factor levels. 22 A one-hour group session with up to 20 participants, with separate sessions for each 23 intervention group, was scheduled after inclusion. Group sessions consisted of informative 24 talks and provision of written material with descriptions of main foods, seasonal shopping

25 lists, meal plans, and cooking recipes.[22]

1 MEASUREMENTS

2 Weight and height were measured with calibrated scales and a wall-mounted stadiometer, 3 respectively. Waist circumference was measured midway between the lowest rib and the iliac 4 crest using an anthropometric tape. Trained personnel measured blood pressure in triplicate 5 with a validated semi-automatic oscillometer (Omron HEM-705CP, The Netherlands). 6 Blood and urine samples were obtained after an overnight fast. Serum, EDTA- plasma, and 7 urine samples were coded, shipped to central laboratories, and stored at -80°C until assay. The 8 clinical investigators and laboratory technicians were blinded to intervention. Analyses 9 determined by subject in frozen samples of whole serum or plasma as appropriate were: blood 10 glucose by the glucose-oxidase method; serum insulin by radioimmunoassay; cholesterol and 11 triglycerides by enzymatic procedures; HDL cholesterol after precipitation with 12 phosphotungstic acid and magnesium chloride; soluble intercellular adhesion molecule-1 13 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and interleukin-6 (IL-6) by 14 standard ELISA assays; and high sensitivity C-reactive protein (CRP) by particle-enhanced 15 immunonephelometry. 16 STATISTICAL ANALYSES 17 For the comparison of changes in risk factors, the average of two baseline measurements was 18 used as the baseline value and the average of the two 3-month measurements was used as the 19 final variable. Values with a skewed distribution (CRP, VCAM-1, ICAM-1 and IL-6) were 20 transformed to their natural logarithm for analyses. Those subjects whose energy intake, as 21 derived from food frequency questionnaires, was outside pre-specified ranges (2510 to 14 644 22 kJ for women and 3347 to 17 573 kJ for men) were excluded from the calculations of energy 23 and nutrient intake, as recommended in nutritional epidemiology. [24] Multiple linear 24 regression models were used to study the relationship between DF and changes in risk factors. 25 Mean differences in the changes of these variables (post-trial minus pre-trial values) were

1	compared by quintiles of change in DF intake. We adjusted for intervention group, age,
2	gender, body weight, smoking, alcohol intake and physical activity. The treatment effects are
3	expressed as average changes and 95% confidence intervals (CI).
4	
5	RESULTS
6	Of the 930 eligible subjects, 158 were excluded for the following reasons: not meeting
7	inclusion criteria (n=86), not accepting to change their dietary habits (n=18), excessive
8	alcohol intake (n=14), gastrointestinal disease (n=4), food allergies (n=3) or refusing to
9	participate (n=33). Table 1 shows the baseline characteristics of the 772 participants (348
10	men and 424 women) who entered the study. Most of them were overweight or obese (90%),
11	more than three quarters had hypertension, one fourth had family history of cardiovascular
12	disease and one fifth were smokers. There were only 3 withdrawals before study completion.
13	The baseline data of these subjects were similar to the mean values for the overall group.
14	Subsequent data refer only to the 769 participants who completed the study.
15	FOOD, ENERGY, AND NUTRIENT INTAKE
16	We excluded 48 participants from food, energy and nutrient calculations because they
17	reported unrealistic energy intakes.[21] Following the advice of the dieticians, most of the
18	participants increased consumption of vegetables, legumes, fruits, and fish and decreased
19	intake of meat and dairy products (Table 2). Cereal intake also decreased due to reduced
20	consumption of white bread, which is the main cereal food in the Spanish diet. A large
21	increase in the consumption of nuts, one of the supplemental foods given, was observed,
22	whereas the total amount of olive oil did not change because participants replaced customarily
23	used refined olive oil by the virgin variety supplied. Alcohol intake increased slightly at the
24	expense of wine, one of the components of the Med-diet recommended in moderation to
25	participants who were not abstainers at baseline. The results did not materially change when
26	we included in the calculations the participants whose energy consumption was out of range.

Table 2 also shows 3-month changes in energy and nutrient intake. The reduction from
baseline in reported energy intake was due to decreases in intake of carbohydrate and total fat,
while protein intake increased. Increases in intake of monounsaturated fatty acids (MUFA)
and polyunsaturated fatty acids (PUFA), including both vegetable and marine n-3 fatty acids,
and a decrease in saturated fatty acid (SFA) intake occurred. Estimated energy expenditure
from physical activity was similar at baseline and after 3 months.

7 FIBRE AND VASCULAR RISK FACTORS

8 A significant increase in total and soluble DF intake was observed at the 3-month assessment 9 (Table 2). However, the consumption of DF exhibited wide between-subject variability. In 10 fact, daily DF intake ranged from 6 to 65 g at the 3-month assessment. Because energy and 11 DF intake increased in parallel, changes in DF intake categorized in quintiles were energy-12 adjusted to assess associations with other variables (Table 3). Demographic characteristics, 13 adiposity and cardiovascular risk factors were similar across the range of DF intake. 14 Predictably, increasing DF intake was associated directly with carbohydrate intake and 15 inversely with intake of total fat, MUFA and SFA. There were no differences in alcohol 16 intake or sedentariness by categories of DF intake. 17 Table 4 shows adjusted changes in risk factors according to quintiles of change in DF. The 18 higher the increment in DF intake, the greater was the weight loss and the reduction in waist 19 circumference and systolic and diastolic blood pressure. In addition, fasting glucose and total 20 cholesterol levels decreased, and HDL cholesterol increased with increasing DF intake. 21 Reductions in serum LDL cholesterol concentrations, but not in triglycerides, were 22 nonsignificantly higher for participants with greater increases in DF. The plasma levels of 23 CRP, a systemic biomarker of inflammation, but not those of other inflammatory biomarkers, 24 also decreased in parallel with increases in DF.

6 (P=0.042) different between extreme quintiles. Changes of cardiovascular risk factors in
7 quintile 5 versus quintile 1 of DF intake ranged from nearly 1 kg reduction in body weight to
8 close to a 9 mm decrease in systolic blood pressure.
9
10 DISCUSSION
11 We tested the hypothesis that the provision of increasing amounts of DF from natural foods

Table 5 shows changes in cardiovascular risk factors between extreme quintiles of DF

intake. The differences were statistically significant for body weight, waist circumference,

systolic and diastolic blood pressure, fasting glucose and total cholesterol. When the same

analysis was performed for changes in soluble DF intake, the results were similar, except for

changes in LDL cholesterol, which were -8.06 mg/dL (95% CI -15.83 to -2.87) significantly

1

2

3

4

5

12 might be instrumental in the effect of a Mediterranean-style diet to reduce the levels of 13 cardiovascular risk factors. The rationale underlying this substudy of the PREDIMED feeding 14 trial was the available epidemiological and clinical trial evidence supporting the association of 15 DF intake with beneficial effects on surrogate markers of cardiometabolic risk, including 16 systemic inflammation.[12,14,25-27] In fact, DF intake after a 3-month behavioural 17 intervention to enhance the Med-diet was associated with significant reductions in body 18 weight, waist circumference, systolic and diastolic blood pressure and fasting glucose, as well 19 as a greater increase in HDL cholesterol. In addition, when we specifically assessed changes 20 in the consumption of soluble DF, participants in the highest quintile also showed a 21 significantly greater reduction in serum LDL cholesterol concentration than those in the 22 lowest quintile. 23 Many epidemiological studies have evaluated the effects of DF on the risk of coronary

- heart disease.[3-6] In a pooled analysis of 10 prospective cohorts,[28] each 10-g/day
- 25 increment of energy-adjusted total DF was associated with a 14% decrease in risk of coronary

1	events and a 27% decrease in risk of coronary death. However, in the only randomised
2	clinical trial designed to examine whether increased intake of DF reduces the risk of
3	myocardial infarction, the DART study, [29] patients with existing coronary heart disease
4	advised to increase DF did not have lower reinfarction rates over a 2-year period.
5	Furthermore, DF advice had no clear effect on coronary or all-cause mortality after longer
6	follow-up.[30] Most likely, as assessed in prospective studies,[28] DF intake with the usual
7	diet is a marker of healthy food choices with an overall cardiovascular benefit, while changing
8	the diet to increase DF at late stages, when clinical consequences of atherosclerosis have
9	developed, may not be protective, as has been shown in a similar situation for antioxidant
10	supplements as opposed to the antioxidant content of the habitual diet.[32] Indeed, a plant-
11	based diet is rich in both fibre and antioxidants. At any rate, increasing DF during 3 months
12	by older individuals at high cardiovascular risk has measurable beneficial effects on several
13	risk factors.
14	Reduced adiposity, particularly in the highest category of DF intake (Tables 4 and 5), was
15	observed in our study. Large prospective studies have reported that consumption of DF is
16	inversely associated with weight and weight gain, [32-34]. A high intake of DF may assist
17	weight loss because of the incomplete digestion and absorption of energy from this type of
18	carbohydrate and the bulky nature of high-fibre foods, with increased demands on chewing
19	and subsequent distension and delayed emptying of the stomach, promoting satiety and thus
20	curtailing energy intake.[25,26,35] Our results further support a beneficial role of fibre-rich
21	diets on weight control.
22	Increasing DF intake was associated with significant blood pressure lowering in our
23	mostly hypertensive participants. Consistently, large prospective studies have reported that
24	increased DF was associated with lower risk of hypertension [36] or lower self-reported blood
25	pressure.[37] A meta-analysis of clinical studies of fibre supplementation[12] also supports an

1 inverse association between fibre and blood pressure. Accordingly, an increase in DF has 2 been recommended by the World Health Organization as a safe and practical approach to 3 cardiovascular risk reduction in hypertensive populations.[38] 4 Our participants who increased DF intake also showed a reduction in fasting glucose 5 levels, extending previous observations of the favourable effects of a diet with abundant fibre-6 rich foods, particularly whole grain, bran and germ intake, on the risk of type 2 diabetes.[9-7 11,39,40] DF reduces the glycemic index of foods, thereby attenuating insulin responses and 8 enhancing insulin sensitivity, [41,42] to which associated weight loss is likely to contribute. 9 Structural fibre is insoluble, whereas natural gel-forming fibres are soluble, [2] and 10 increasing consumption of this particular variety of DF has a modest cholesterol lowering 11 effect that is attributable to interference with intestinal bile acid absorption and enhancement 12 of faecal cholesterol excretion, although other mechanisms can be operative. [42] Thus, 13 increasing soluble fibre intake by 1 g/day is associated with a mean reduction in serum LDL 14 cholesterol level of about 2 mg/dL (0.052 mmol/L), according to a meta-analysis of 15 randomized trials of soluble fibre supplementation.[13] In support of these evidences, our 16 study shows a significant -8.06 mg/dL LDL cholesterol decrease between extreme quintiles of 17 soluble fibre intake. 18 Since atherosclerosis is considered a low-grade inflammatory disease, [43] the relationship 19 between DF intake and serum inflammatory markers has also been evaluated in epidemiologic 20 and clinical studies, as reviewed. [25-27] Results from recent epidemiologic studies have 21 consistently shown an inverse association between DF intake and plasma CRP levels.[44-47]

22 In a recent study, both increasing fibre intake by about 30 g/day from a diet naturally rich in

- 23 fibre or from a supplement reduced levels of CRP.[48] Thus, it was not surprising that we
- observed in the upper quintile of energy-adjusted DF intake (≤26 g/day) a nearly 1 mg/L
- 25 reduction in CRP levels after adjustment for sex, age, BMI and relevant lifestyle

characteristics. However, no changes were observed in other inflammatory biomarkers. The
 mechanisms of change in CRP levels as a result of DF intake are still largely unknown.
 Possibilities include DF slowing absorption of glucose, fibre-rich meal modulation of
 cytokine responses blunting oxidative stress and inflammation, and production of anti inflammatory cytokines by gut flora exposed to fibre.[26,27]

6 Our study has limitations. Since no biomarker of DF intake is available, FFQ data was the 7 only source of information on food consumption, including DF. FFQs are known to contain 8 measurement errors, a reason why energy intake was included as a covariate in the models to 9 achieve the equivalent of an isoenergetic diet and thus overcome this problem. At any rate, 10 measurement error most likely would have introduced non-differential misclassification, and 11 the implications for the results of this error would have been to bias the estimates towards the 12 null. The duration of follow-up lasting only 3 months cannot be considered a major limitation, 13 because the effects of dietary interventions on risk factors do not need a long induction 14 period.[49] The study also has strengths, such as reproducing real-life conditions with home-15 prepared foods in free-living individuals, as in usual clinical practice. Other strengths are the 16 high response and low drop-out rates, which can be partly explained because participants 17 belonging to a Mediterranean culture, where people are accustomed to using olive oil and 18 nuts, the supplemental foods provided at no cost, and enjoy eating fibre-rich vegetables, fruits 19 and legumes. 20 In summary, the results of this study show that an increase in DF intake achieved with

natural foods in the setting of a Mediterranean-style diet can reduce cardiovascular risk
factors. Except for subjects in the highest 20% of DF intake, the effects on each individual
risk factor were modest but, taken together, they suggest that increasing DF consumption may
be instrumental in modifying the population cardiovascular risk profile, therefore preventing
or delaying future cardiovascular events.

26

1 ACKNOWLEDGEMENTS

2	We thank the participants for their enthusiastic collaboration and all the PREDIMED
3	personnel for excellent assistance with all aspects of the trial. The authors are grateful to grant
4	support by the Spanish Minister of Health (RTIC G03/140 and RD06/0045), the FIS 070473,
5	Centro Nacional de Investigaciones Cardiovasculares (CNIC06) and MADAUS Pharm for
6	their collaboration in the study. Emili Corbella provided expert assistance with statistical
7	analyses. CIBEROBN is an initiative of Instituto de Salud Carlos III, Spain.
8	
9	WHAT IS ALREADY KNOWN ON THIS SUBJECT?
10	• Epidemiological studies have suggested that dietary fibre intake is associated with
11	reduced incidence of ischemic heart disease, stroke and diabetes.
12	• Clinical trials have also pointed out that diets with fibre supplementation may reduce
13	blood pressure, improve lipid profile and increase insulin sensitivity.
14	• No intervention studies have evaluated the effects of dietary fibre on classical and
15	novel risk factors in free-living subjects at high cardiovascular risk.
16	
17	WHAT DOES THIS PAPER ADD?
18	• The increase of dietary fibre in an intervention aimed to upgrade consumption of
19	fruits, vegetables and legumes in the setting of a Mediterranean-style diet was
20	associated with reductions in cardiovascular risk factors, such as body weight, waist
21	circumference, systolic and diastolic blood pressures, serum glucose, and C-reactive
22	protein.
23	• Reductions in total cholesterol and LDL cholesterol were observed only among
24	participants with greater increases in soluble fibre intake.
25	• These beneficial effects on surrogate markers of cardiovascular risk add biological
26	plausibility to the epidemiological evidence supporting a protective effect of dietary
27	fibre intake on the risk for cardiovascular diseases.
28	

REFERENCES

- 1. Willett WC, Sacks FM, Trichopoulou A, Descher G, Ferro-Luzzi A, Helsing E, et al. Mediterranean diet pyramid: a cultural model for healthy eating. *Am J Clin Nutr* 1995;**61(Suppl 6)**:1402-1406.
- 2. Panel of Definition of Dietary Fiber, Standing Committee on the Scientific Evaluation of Dietary Referent Intakes, Food and Nutrition Board, Institute of Medicine. *Dietary Reference Intakes: Proponed Definition of Dietary Fiber*. Washington, DC: National Academies Press, 2001.
- **3.** Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit and cereal fiber intake and risk of coronary heart disease among women. *JAMA* 1996;**275**:447-451.
- **4.** Todd S, Woodward M, Tunstall-Pedoe H, Bolton.Smith C. Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes-mortality: results from the Scottish Heart Health Study. *Am J Epidemiol* 1999;**150**:1073-1080.
- **5.** Liu S, Buring JE, Sesso HD, Rimm EB, Willett WWC, Manson JE. A prospective study of dietary fiber intake and risk of cardiovascular disease among women. *J Am Coll Cardiol* 2002;**39**:49-56.
- 6. Mozaffarian D, Kumanyika SK, Lemaitre RN, Olson JL, Burke GL, Siscovick DS. Cereal, fruit and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals. *JAMA* 2003;**289**:1659-1666.
- 7. Ascherio A, Rimm EB, Hernan MA, Giovannucci EL, Kawachi I, Stamfer MJ, et al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. *Circulation* 1998;**98**:1198-1204.
- 8. Oh K, Hu FB, Cho E, Rexrode KM, Stampfer MJ, Manson JE, Liu S, Willett WC. Carbohydrate intake, glycemic index, glycemic load, and dietary fiber in relation to risk of stroke in women. *Am J Epidemiol* 2005;**161**:161-169.
- **9.** Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. *JAMA* 1997;**277**:472–477.
- Meyer KA, Kushi LH, Jacobs DR Jr, Slavin J, Sellers TA, Folsom AR. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. *Am J Clin Nutr* 2000;**71**:921–930.
- **11.** Liu S. Whole-grain foods, dietary fiber, and type 2 diabetes: searching for a kernel of truth. *Am J Clin Nutr* 2003;**77**:527–529.
- **12.** Streppel MT, Arends LR, van't Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure. A meta-analysis of randomized placebo-controlled trials. *Arch Intern Med* 2005:**165**:150-156.

- **13.** Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr* 1999;**69**:30-42.
- **14.** Anderson JW. Dietary fiber prevents carbohydrate-induced hypertriglyceridemia. *Curr Atheroscler Rep* 2000;**2**:536-541.
- **15.** Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM,, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000;**342**:1392-1398.
- 16 Ludwig DS, Pereira MA, Kroenke CH, Hilner JE, van Horn L, Slattery ML, Jacobs DR Jr. Dietary fiber, weight gain, and cardiovascular disease risk factors in younger adults. *JAMA* 1999;**282**;1539-1546.
- Estruch R, Martínez.González MA, Corella D, Salas-Salvadó J, Ruiz-Guitérrez V, Covas MI, et al. Effects on a Mediterranean-style diet on cardiovascular risk factors. A randomized trial. *Ann Intern Med* 2006;**145**:1-11.
- **18.** Nigg CR, Burbank PM, Padula C, Dufresne R, Rossi JS, Velicer WF, et al. Stages of change across ten health risk behaviors for older adults. *Gerontologist* 1999;**39**:473-82.
- **19.** Martín-Moreno JM, Boyle P, Gorgojo L, Maisonneuve P, Fernández-Rodríguez JC, Salvini S, et al. Development and validation of a food frequency questionnaire in Spain. *Int J Epidemiol* 1993;**22**:512-9.
- **20.** Elosua R, Marrugat J, Molina L, Pons S, Pujol E. Validation of the Minnesota Leisure Time Physical Activity Questionnaire in Spanish Men. *Am J Epidemiol* 1994;**139**:1197-1209.
- **21.** Mataix J. *Tabla de Composición de Alimentos Españoles*, 4th ed. Universidad de Granada, Granada, Spain, 2003.
- **22.** Zaspe I, Sanchez-Tainta A, Estruch R, Lamuela-Raventós RM, Schröeder H, Salas-Salvadó J, et al. A large randomized individual and group intervention conducted by registered dietitians increased adherence to Mediterranean-type: the PREDIMED study. *J AmDiet Assoc* **2008**;108:1134-1144.
- **23.** Krauss RM, Eckel RH, Howard B, Apple LJ, Daniels SR, Deckelbaum RJ, et al. AHA dietary guidelines. Revision 2000: A statement for healthcare professionals from nutrition committee of the American Heart Association. *Circulation* 2000;**102**:2284-2299.
- 24. Willett WC. Issues in analysis and presentation of dietary data. In: Willett WC. *Nutritional Epidemiology*. New York: Oxford University Press, 1998; 321-45.
- **25**. Bulló M, Casas-Agustench P, Amigó-Correig P, Aranceta J, Salas-Salvadó J. Inflammation, obesity and comorbidities: the role of diet. *Public Health Nutr* 2007;**10**:1164-1172.

- **26.** Weickert MO, Pfeiffer AFH. Metabolic effects of dietary fiber consumption and prevention of diabetes. *J Nutr* 2008;**138**:439-442.
- 27. O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary strategies for improving postprandial glucose, lipids, inflammation, and cardiovascular health. *J Am Coll Cardiol* 2008;**51**:249-255.
- **28.** Pereira MA, O'Reilly E, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. *Arch Intern Med* 2004;**164**:370-376.
- **29.** Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757–761.
- **30.** Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD, Burr ML. The long term effect of dietary advice in men with coronary disease: follow-up of the Diet and Reinfarction trial (DART). *Eur J Clin Nutr* 2002;**56**:512-518
- **31.** Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. *Lancet* 2003; **361**:2017–2023.
- **32.** Liu S, Willett WC, Manson JE, Hu FB, Rosner B, Colditz G. Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. *Am J Clin Nutr* 2003;**78**:920-927.
- **33.** Koh-Banerjee P, Franz M, Sampson L, Liu S, Jacobs DR Jr, Spiegelman D, Willett W, Rimm E. Changes in whole-grain, bran, and cereal fiber consumption in relation to 8-y weight gain among men. *Am J Clin Nutr* 2004;**80**:1237–1245.
- **34.** Bes-Restrollo M, Martínez-González MA, Sánchez-Villegas A, de la Fuente Arrillaga C, Martínez JA. Association of fiber intake and fruit/vegetable consumption with weight gain in a Mediterranean population. *Nutrition* 2006;**22**:504-511.
- **35.** van Dam RM, Seidell JC. Carbohydrate intake and obesity. *Eur J Clin Nutr* 2007;**61 Suppl 1:**S75-99.
- **36.** Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, Sacks F, Stampfer MJ. A prospective study of nutritional factors and hypertension among US men. *Circulation* 1992;**86**:1475-1484.
- **37.** Ascherio A, Hennekens C, Willett WC, Sacks F, Rosner B, Manson J, Witteman J, Stampfer MJ. Prospective study of nutritional factors, blood pressure, and hypertension among US women. *Hypertension* 1996;**27**:1065-1072.
- **38.** WHO. Population nutrient intake goals for preventing diet-related chronic diseases. In: Diet, nutrition and the prevention of chronic diseases. *WHO Technical report Series* 2003;**916**:46-83.

- **39.** Montonen J, Knekt P, Jarvinen R, Aromaa A, Reunanem A. Whole grain and fiber intake and the incidence of type 2 diabetes. *Am J Clin Nutr* 2003;**77**:622-629.
- **40.** van Dam RM, Hu FB, Rosenberg L, Krishnan S, Palmer JR. Dietary calcium and magnesium, major food sources, and risk of type 2 diabetes in U.S. black women. *Diabetes Care* 2006;**29**:2238-43.
- **41.** Bessesen DH. The role of carbohydrates in insulin resistance. *J Nutr* 2001;**131**:2782S-2786S.
- **42.** Jenkins DJ, Kendall CW, Axelsen M, Augustin LS, Vuksan V. Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease. *Curr Opin Lipidol* 2000;**11**:49-56.
- **43.** Hanson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005;**352**:1685-1695.
- **44.** Ajani UA, Ford ES, Mokdad AH. Dietary fiber and C-reactive protein: findings from National Health and Nutrition Examination Survey data. *J Nutr* 2004;**134**:1181-1185.
- **45.** Ma Y, Griffith JA, Chasan-Taber L, Olendzki BC, Jackson E, Satnek III EJ, Li W, Pagoto SL, et al. Association between dietary fiber and serum C-reactive protein. *Am J Clin Nutr* 2006; **83**:760-766.
- **46.** Qi L, van Dam RM, Liu S, Franz M, Mantzoros C, Hu FB. Whole-grain, bran, and cereal fiber intakes and markers of systemic inflammation in diabetic women. *Diabetes Care* 2006;**29**:207-211.
- **47.** Ma Y, Hébert JR, Li W, Bertone-Johnson ER, Olendzki B, Pagoto SL, et al. Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study. *Nutrition* 2008;**24**:941-949.
- **48.** King DE, Egan BM, Woolson RF, Mainous III AG, Solaiman YA, Jesri A. Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein level. *Arch Intern Med* 2007;**167**:502-506.
- **49.** Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. *N Engl J Med* 2001;**344**:3-8

LICENCE FOR PUBLICATION STATEMENT

"The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in JECH and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence (<u>http://jmg.bmj.com/ifora/licence.pdf</u>)."

Table 1. Baseline characteristics of the 772 subjects included in the study.

Characteristics	Participants
Age, mean (SD), years	68.8 (6.4)
Gender, men (%)	339 (44)
Family history of CHD, No. (%)	178 (23)
Current smokers, No. (%)	127 (16)
Type 2 diabetes mellitus, No. (%)	421 (54)
Hypertension, No (%)	605 (78)
Dyslipidemia, No. (%)	515 (67)
Body mass index, mean (SD), kg/m ²	29.9 (4.2)
Overweight or obesity	696 (90)
(Body mass index > 25 kg/m ²), No. (%)	
Medications, No. (%)	
ACE inhibitors	340 (44)
Diuretics	271 (35)
Other antihypertensive agents	160 (21)
Statins	326 (42)
Other lipid-lowering agents	51 (6)
Insulin	61 (8)
Oral hypoglycemic drugs	282 (37)
Aspirin or other antiplatelet drugs	138 (18)
Occupation, No. (%)	
Unskilled	179 (23)
Skilled manual	288 (37)
Skilled non-manual	172 (22)
Directive and professional	133 (17)
Education level, No. (%)	
Primary school	554 (72)
First degree high school	126 (16)
High school or university	91 (12)

Abbreviations: CHD, coronary heart disease; ACE, angiotensin-converting enzyme.

[†]Calculated as weight in kilograms divided by the square of height in meters.

Variables	Baseline	3 months	Change, mean (95 % CI)	Р
Foods, daily consumption in g	rams			
Fruits	262 <u>+</u> 218	280 <u>+</u> 153	18.1 (0.4 to 35.7)	0.044
Vegetables	357 <u>+</u> 168	362 <u>+</u> 164	5.1 (-8.0 to 18.2)	0.443
Legumes	14.3 <u>+</u> 9.3	19.5 <u>+</u> 21.5	5.2 (3.6 to 6.9)	< 0.001
Fish, seafood	111 <u>+</u> 63	114 <u>+</u> 87	2.6 (-3.6 to 8.8)	0.414
Meat, meat products	157 <u>+</u> 75	136 <u>+</u> 58	-20.6 (-26.6 to -15.2)	< 0.001
Cereals	263 <u>+</u> 124	238 <u>+</u> 115	-24.8 (-34.4 to -15.2)	< 0.001
Dairy products	403 <u>+</u> 228	387 <u>+</u> 226	-16.1 (-32.1 to -0.2)	0.047
Refined-mixed olive oil	20.5 <u>+</u> 20.7	13.6 <u>+</u> 19.5	-6.9 (-8.6 to -5.1)	< 0.001
Virgin olive oil	19.9 <u>+</u> 23.9	27.6 <u>+</u> 23.8	7.7 (5.9 to 9.4)	< 0.001
Total nuts	11.0 <u>+</u> 16	22.1 <u>+</u> 23.5	11.1 (9.1 to 13.1)	< 0.001
Alcohol	10.5 <u>+</u> 17.3	12.3 <u>+</u> 18.4	1.9 (0.6 to 3.1)	0.003
Energy and Nutrients				
Energy, kj/d	2538 <u>+</u> 738	2393 <u>+</u> 638	-145 (-200 to -88)	< 0.001
Protein, % En	17.1 <u>+</u> 3.3	18.8 <u>+</u> 6.0	1.7 (1.2 to 2.3)	< 0.001
Carbohydrate, % En	41.9 <u>+</u> 7.7	41.0 <u>+</u> 7.7	-0.9 (-1.5 to -0.3)	< 0.001
Total fibre, g/d	21.1 <u>+</u> 7.6	22.2 <u>+</u> 7.9	1.1 (0.4 to 1.7)	0.001
Soluble fibre, g/d	5.5 <u>+</u> 2.1	5.9 <u>+</u> 2.0	0.4 (0.2 to 0.6)	< 0.001
Total fat, % En	38.2 <u>+</u> 7.3	37.2 <u>+</u> 9.1	-0.8 (-1.5 to -0.1)	0.020
MUFA	18.8 <u>+</u> 4.6	19.3 <u>+</u> 4.6	0.5 (0.1 to 0.8)	0.009
PUFA	6.8 <u>+</u> 2.2	7.2 <u>+</u> 3.2	1.0 (0.8 to 1.3)	< 0.001
SFA	10.1 <u>+</u> 2.4	9.2 <u>+</u> 2.2	-0.8 (-1.0 to -0.7)	< 0.001
Alpha-linolenic acid, g/d	1.5 <u>+</u> 0.9	1.9 <u>+</u> 1.4	0.4 (0.3 to 0.5)	< 0.001
Marine n-3 fatty acids, g/d	0.8 <u>+</u> 0.6	0.9 <u>+</u> 0.9	0.1 (0.0 to 0.2)	0.009

Table 2. Baseline levels and 3-month changes in the consumption of key food items, energy and nutrients.

CI, Confidence Interval, MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids.

Table 3. Subjects characteristics and energy	and nutrient intake according to quintiles of energy-
adjusted dietary fibre intake at 3 months.	

Variables	Quintiles of energy-adjusted total fibre intake at baseline					_
	Q1	Q2	Q3	Q4	Q5	P*
N	144	146	143	143	145	
Dietary fibre intake, g/d	≤16	16.1-19.9	20.0-21.9	22.0-25.9	≥26.0	
(median)	(14)	(18)	(21)	(23)	(29)	
Age, years	68.7 <u>+</u> 5.6	69.3 <u>+</u> 6.0	68.4 <u>+</u> 6.5	68.9 <u>+</u> 6.0	69.2 <u>+</u> 7.6	0.667
Sex, men	60	77	62	64	64	0.609
Smokers, n (%)	27 (19)	26 (18)	24 (17)	17 (12)	28 (19)	0.733
Diabetes, n (%)	79 (55)	95 (65)	77 (54)	75 (52)	85 (59)	0.470
Hypertension, n (%)	125 (87)	130 (89)	111 (78)	108 (76)	112 (77)	0.294
Dyslipidemia, n (%)	105 (73)	100 (69)	88 (62)	107 (75)	94 (65)	0.126
Body mass index, kg/m ²	29.6 <u>+</u> 4.0	30.0 <u>+</u> 4.5	30.0 <u>+</u> 4.5	29.7 <u>+</u> 4.0	29.3 <u>+</u> 3.9	0.608
Waist circumference, cm	101 <u>+</u> 10	101 <u>+</u> 12	100 <u>+</u> 11	99 <u>+</u> 13	98 <u>+</u> 10	0.174
Energy, kcal/d	2059 <u>+</u> 590	2324 <u>+</u> 520	2538 <u>+</u> 598	2824 <u>+</u> 724	3065 <u>+</u> 886	< 0.001
Protein, % En	17.6 <u>+</u> 3.8	17.2 <u>+</u> 2.9	16.9 <u>+</u> 3.4	16.6 <u>+</u> 2.9	16.8 <u>+</u> 2.8	0.043
Carbohydrate,% En	40.6 <u>+</u> 8.5	40.3 <u>+</u> 7.6	41.5 <u>+</u> 6.9	43.7 <u>+</u> 6.8	45.2 <u>+</u> 6.8	< 0.001
Fat, % En	38.3 <u>+</u> 7.9	39.7 <u>+</u> 7.3	38.9 <u>+</u> 7.2	37.4 <u>+</u> 6.1	35.8 <u>+</u> 6.1	< 0.001
MUFA	18.8 <u>+</u> 5.0	19.8 <u>+</u> 2.5	19.3 <u>+</u> 4.6	18.3 <u>+</u> 4.1	16.9 <u>+</u> 3.8	< 0.001
PUFA	5.8 <u>+</u> 2.1	6.2 <u>+</u> 1.8	6.2 ± 2.2	6.0 ± 1.8	6.3 <u>+</u> 2.7	0.215
SFA	10.7 <u>+</u> 2.7	10.4 <u>+</u> 2.5	10.1 <u>+</u> 2.2	9.8 <u>+</u> 2.1	9.6 <u>+</u> 2.4	< 0.001
Virgin olive oil, g/d	13.8 <u>+</u> 20.9	18.8 <u>+</u> 22.8	19.5 <u>+</u> 23.1	24.1 <u>+</u> 25.4	20.0 <u>+</u> 23.4	0.010
Alcohol, g/d	11.8 <u>+</u> 22.7	9.9 <u>+</u> 16.7	10.8 <u>+</u> 16.8	9.1 <u>+</u> 13.5	9.2 <u>+</u> 11.7	0.754
Low physical activity, n (%)**	47 (34)	45 (32)	46 (33)	35 (25)	32 (23)	0.155

Abbreviations as in Table 2.

Values are means \pm standard deviations unless otherwise stated

* P value for linear trend by ANOVA or chi-square test.

**Lowest tertile.

	Quintiles of change in dietary fibre intake						
Variable changes	Q1	Q2	Q3	Q4	Q5	P*	P**
Fibre intake, range (g/d)	<-2.5	-2.5 to 0.2	0.2 to 1.8	1.8 to 5.3	>5.3		
Fibre intake, median (g/d)	-5.7	-1.3	0.3	2.6	8.3		
Ν	122	123	123	122	123		
Weight, kg	0.02	-0.19	-0.23	-0.38	-0.90	< 0.001	0.001
Waist circumference, cm	0.74	-0.17	-0.83	-1.27	-1.90	< 0.001	< 0.001
Systolic BP, mm Hg	-0.19	-2.67	-2.95	-2.43	-9.08	< 0.001	< 0.001
Diastolic BP, mm Hg	-1.25	-1.33	-2.04	-2.01	-4.76	0.002	0.005
Fasting glucose, mg/dL	5.72	1.84	-3.56	-1.65	-7.67	0.05	0.04
Fasting insulin, pmol/L	-0.53	0.51	-0.68	-0.52	-0.77	0.81	0.76
Total cholesterol, mg/dL	0.94	-2.75	0.95	-5.52	-8.78	0.14	0.19
LDL cholesterol, mg/dL	-1.66	-2.15	-3.77	-5.09	-8.63	0.14	0.14
HDL cholesterol, mg/dL	1.29	0.81	1.46	1.51	2.32	0.07	0.02
Triglycerides, mg/dL	-5.09	-4.20	0.70	-2.23	-3.62	0.80	0.70
C-reactive protein, mg/L	-0.02	-0.03	-0.18	-0.21	-1.01	0.07	0.04
Interleukin-6, pg/mL	-0.46	-1.18	0.21	-0.65	-0.69	0.90	0.88
ICAM-1, ng/mL	-14.6	-27.1	-39.6	-23.3	-22.6	0.81	0.82
VCAM-1, ng/mL	-21	-17	22	-117	-77	0.19	0.23

Table 4. Three-month changes in risk factors by quintiles of change in dietary fibre intake.

BP, blood pressure; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule.

* P value for linear trend adjusted for age, gender and energy intake.

** Additionally adjusted for intervention group and baseline body mass index, smoking, alcohol intake and physical activity.

Table 5. Mean changes (95% confidence intervals) and mean differences (95% confidence intervals) in changes in adiposity, blood pressure and other risk factors between the lowest (Q1) and the highest (Q5) quintile of changes in total dietary fibre intake.

Variable changes	Extremes of changes in dietary fibre intake				
	Q1	Q5	Change Q5 versus Q1*	P **	
Weight, kg	0.02 (-0.36 to 0.32)	-0.90 (-1.40 to -0.42)	-0.92 (-1.52 to -0.33)	0.002	
Waist circumference, cm	0.74 (-0.20 to 1.68)	-1.90 (-3.18 to -0.60)	-2.63 (-4.20 to -1.07)	0.001	
Systolic blood pressure, mm Hg	-0.19 (-3.41 to 3.03)	-9.08(-12.21 to -5.95)	-8.89 (-13.37 to -4.41)	< 0.001	
Diastolic blood pressure, mm Hg	-1.25 (-2.70 to 0.21)	-4.76 (-6.46 to -3.08)	-3.52 (-5.73 to -1.31)	0.002	
Fasting glucose, mg/dL	5.72 (0.64 to 10.79)	-7.67 (-11.84 to -3.50)	-13.39 (-19.86 to -6.93)	< 0.001	
Total cholesterol, mg/dL	0.94 (-5.24 to 7.12)	-8.78 (-14.30 to -3.27)	-9.73 (-17.96 to -1.49)	0.021	
LDL cholesterol, mg/dL	-1.66 (-6.96 to 3.64)	-8.63 (-14.26 to -3.00)	-7.90 (-14.96 to 0.72)	0.075	
HDL cholesterol, mg/dL	1.29 (0.08 to 2.52)	2.32 (1.08 to 3.57)	1.03 (-0.70 to 2.76)	0.242	
C-reactive protein, mg/L	-0.02 (-0.51 to 0.48)	-1.01 (-1.53 to -0.49)	-1.08 (-1.80 to -0.48)	0.004	

* Differences between baseline and 3-month follow-up evaluation.